US Infectious Disease Therapeutics Market Analysis

US Infectious Disease Therapeutics Market Executive Summary

The market for therapies for infectious diseases in the US is anticipated to increase from $50.3 billion in 2022 to $60.6 billion in 2030, recording a CAGR of 2.35% for the forecast period of 2022–30.

The therapeutics market for infectious diseases in the US is a sizable and quickly developing area of the pharmaceutical business. Infectious disorders may spread from person to person or via contaminated food, water, or other environmental sources. They are brought on by pathogenic microorganisms such as bacteria, viruses, fungi, and parasites. Drugs and vaccines used to treat and prevent infectious illnesses are included in the market for infectious disease treatments.

The rising prevalence of infectious illnesses, the advent of novel, drug-resistant microorganisms, and the rising need for efficient treatments and preventative measures are some of the factors driving the US infectious disease therapeutics market. With the development of vaccinations and treatments to treat the virus, the COVID-19 pandemic has also had a substantial influence on the market.

One of the most often prescribed medicine classes for infectious disorders is an antibiotic, however as antibiotic-resistant bacteria have grown in prevalence, new antibiotics and other treatments including antivirals and antifungals have been created.

Biologics, such as monoclonal antibodies, and vaccines, which have grown in significance in the prevention and treatment of infectious illnesses, are also included in the market for infectious disease treatments along with conventional medicines.

Via financing for R&D, regulatory supervision, and public health efforts, the US government has a big influence on the market for treatments for infectious diseases. Two significant gov organizations active in the study of infectious diseases and public health initiatives are the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC).

The rising prevalence of infectious illnesses and the advent of novel, drug-resistant microorganisms are just a few of the causes driving the US infectious disease therapeutics market, which is a sizable and dynamic area of the pharmaceutical industry.

Market Dynamics

Growth Drivers

Many important aspects, such as the following, are what drive the US infectious illness treatments market:

1. Increasing incidence of infectious diseases: The need for medications that can cure or prevent infectious diseases including HIV/AIDS, hepatitis, influenza, and TB is rising as these illnesses become more common.
2. The emergence of novel, medication-resistant pathogens: Novel, medication-resistant pathogens, including antibiotic-resistant bacteria and novel influenza strains, have necessitated the creation of novel, inventive medicines.
3. Growing demand for effective treatments and preventative measures, such as vaccinations, that may help stop the spread of infectious diseases is being driven by the public's rising awareness of the hazards connected with these illnesses.
4. Technological developments researchers have been able to create novel and more potent treatments for infectious illnesses because of technological advancements including genomics, proteomics, and high-throughput screening.
5. Government funding and support: The US government generously funds and supports the study and development of infectious diseases, which has sparked new product development.
6. Initiatives related to public health: By raising awareness and encouraging the adoption of preventative measures, public health efforts such as vaccination campaigns and disease monitoring programs have also contributed to the expansion of the market for treatments for infectious diseases.
7. COVID-19 pandemic: The COVID-19 pandemic has had a substantial influence on the market, stimulating demand and investment in the field of infectious disease therapies. This is because vaccines and other treatments to treat the virus have been developed.

Competitive Landscape

Key Players

The US infectious disease therapeutics market is highly competitive, with numerous players operating in the sector. Some of the major players in this market include:

• Gilead Sciences, Inc.
• Merck & Co., Inc.
• Johnson & Johnson
• Pfizer Inc.
• Roche Holding AG
• Sanofi
• AbbVie Inc.
• GlaxoSmithKline plc
• Novartis International AG
• Eli Lilly and Company

Healthcare Policies and Regulatory Landscape

The development, approval, and marketing of novel drugs may be impacted by a variety of healthcare regulations and laws that apply to the US market for therapies for infectious diseases. Many of the important laws and agencies in charge of regulating this market are as follows:

1. Food and Drug Administration (FDA): In the US, the FDA is in charge of overseeing the development, evaluation, and marketing of medications and biologics for infectious illnesses. Pre-market safety and effectiveness assessments are carried out by the Center for Drug Evaluation and Research (CDER) of the FDA.
2. The US government's Biomedical Advanced Research and Development Authority (BARDA) promotes the creation and purchase of medical countermeasures, such as medications, vaccines, and diagnostics, for infectious illnesses and other risks to public health.
3. National Institute of Allergy and Infectious Diseases (NIAID): NIAID is a branch of the National Institutes of Health (NIH) that promotes the study of medicines and vaccines for infectious illnesses such as COVID-19, HIV/AIDS, and TB.
4. The Orphan Drug Act (ODA) offers incentives, including market exclusivity and tax benefits, to promote the development of pharmaceuticals and biologics for rare disorders, including certain infectious diseases.
5. The Limited Population Route for Antibacterial and Antifungal Medicines (LPAD) is a regulatory process created by the FDA to hasten the development and approval of antibiotics and antifungal medications for severe or life-threatening illnesses that afflict a small number of people.
6. Priority Review Voucher (PRV) Program: The PRV program rewards sponsors who develop medications and biologics for rare pediatric disorders and neglected tropical diseases by giving them vouchers that may be used to have another drug application quickly reviewed by the FDA.
7. The Global Health Security Agenda (GHSA) is an international collaboration with the goal of improving the world's readiness and response to infectious disease risks, such as outbreaks of new and reemerging infectious diseases.

By encouraging the creation of new medicines, providing financing and support for research, and defining regulatory standards for safety and effectiveness, these laws and regulatory organizations significantly influence the infectious disease therapies industry in the US.